What Prevents Chemo-Linked HFS?

Network meta-analysis compares preventive agents for chemotherapy-induced hand-foot syndrome

1

Topical diclofenac and silymarin reduced the risk of hand-foot syndrome (HFS) in chemotherapy patients, according to a systematic review.
2

HFS is a dose-dependent toxic effect commonly seen with capecitabine, presenting with erythema, edema, and dysesthesia.
3

Four interventions, including diclofenac gel and celecoxib, significantly reduced grade 2 or higher HFS compared to placebo.
4

Diclofenac showed the most consistent evidence for preventing HFS, while silymarin's findings were based on a small trial.
5

The study highlighted the need for larger trials to confirm silymarin's efficacy and noted limitations in generalizability.

1